<!DOCTYPE html><html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8"><meta name="format-detection" content="telephone=no"><meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no"><link rel="stylesheet" href="css/main.min.css"><script src="js/all.min.js"></script><script type="text/javascript">var slideNumber = 13</script></head><body class="s13"><div class="content-wrap"><nav><div onclick="iRep.go(1)" class="home-button"></div><ul><li onclick="iRep.go(3)" class="real-world-evidence"><span>REAL WORLD</span></li><li onclick="iRep.go(4)" class="evidence"><span>EVIDENCE</span></li><li onclick="iRep.go(12)" class="reversal active"><span>REVERSAL</span></li><li onclick="iRep.go(14)" class="take-action"><span>COST</span></li><li onclick="iRep.goToolbox()" class="toolbox"><span>TOOLBOX</span></li><li onclick="iRep.go(16)" class="pi"><span>PI</span></li></ul></nav><div class="page-nav"><div onclick="iRep.nextSlide()" class="page-next"></div><div onclick="iRep.prevSlide()" class="page-prev"></div></div><article><h1>Pradaxa<sup>®</sup>: The only NOAC with immediate reversal in rare<br/> emergency situations<sup>1–5</sup></h1><h3>Praxbind<sup>®</sup> offers:</h3><div class="big-image"></div></article><div class="sidetab"><ul class="trans"><li class="findThisByScript"><span>Mode of action</span></li><li id="showHigher" class="findThisByScript"><span>efficacy</span></li><li class="findThisByScript"><span>dosing</span></li><li class="findThisByScript"><span>administration</span></li></ul><div class="tab-panels"><div id="panel1" class="panel"><div class="close-button close"></div><h2>Praxbind<sup>®</sup>: Mode of action</h2><div class="blue-box"><p>Praxbind<sup>®</sup> has a 300-fold greater affinity for Pradaxa<sup>®</sup> than Pradaxa<sup>®</sup> has for thrombin<sup>1,2</sup></p><p>Praxbind<sup>®</sup> rapidly binds to both free and thrombin-bound Pradaxa<sup>®1,2</sup></p></div><div class="bg"></div><div class="basket"><div class="circle add fragment1"></div><div class="circle value"><span>0</span><div>0</div></div></div><p class="footnotes"><strong>References: 1.</strong> Schiele F <em>et al. Blood</em> 2013;121:3554–3562. <strong>2.</strong> Boehringer Ingelheim. Praxbind<sup>®</sup> Summary of Product Characteristics.</p></div><div id="panel2" class="panel"><div class="close-button close"></div><div class="text"></div><div class="ref"><b>References: 1.</b> Pollack C<em> et al. NEJM</em> 2015;377:511–520.<b> 2.</b> Levy JH<em> et al.</em> Poster at ESC Congress, London, UK, 29 August–2 September 2015.</div></div><div id="panel3" class="panel"><div class="close-button close"></div><!--h2 Praxbind<sup>®</sup>: Dosing<sup>1</sup>--><div class="title-image"></div><h3>Praxbind<sup>®</sup> immediately reverses the anticoagulant effects<br/>of Pradaxa<sup>®</sup> after the administration of the complete<br/>5 g dose<sup>1</sup></h3><h3 class="blue">The dose is 5 g:<sup>1</></h3><div class="list"><p><span class="bull">&bull;</span> Two 50 ml vials = one dose of Praxbind<sup>®</sup> (2 x 2.5 g)</p><p><span class="bull">&bull;</span> Ready-to-use solution for IV administration</p><p><span class="bull">&bull;</span> A fixed dose for all patients – no adjustment required</p><p class="indent">or elderly, or for those with impaired renal or</p><p class="indent">hepatic function</p></div><div class="bottle"></div><p class="footnotes">IV: Intravenous.<br/><strong>Reference: 1.</strong> Boehringer Ingelheim. Praxbind<sup>®</sup> Summary of Product Characteristics.</p></div><div id="panel4" class="panel"><div class="close-button close"></div><!--h2 Praxbind<sup>®</sup>: Administration<sup>1</sup>--><div class="title-image"></div><div class="panel4-list"></div><div class="plug"></div><p class="footnotes">IV. Intravenous<br/><strong>Reference: 1.</strong> Boehringer Ingelheim. Praxbind<sup>®</sup> Summary of Product Characteristics.</p></div></div></div><div class="overlay"></div><div class="sidebar"><ul><li class="references-tab tab"></li></ul><div class="panel"><div class="close-button"></div><div class="content references"><div class="text"> <strong>References: 1.</strong> Boehringer Ingelheim. Pradaxa<sup>®</sup> Summary of Product Characteristics.
 <strong>2.</strong> Boehringer Ingelheim. Praxbind<sup>®</sup> Summary of Product Characteristics.<br/><strong>3.</strong>
 Schiele F <em>et al. Blood</em> 2013;121(18):3554–3562.
 <strong>4.</strong> Sarich TC <em>et al. Am Heart J</em> 2015;169(6):751–757.
 <strong>5.</strong> Pollack CV <em>et al. N Engl J Med</em> 2015;373(6):511–520.</div></div></div></div><div class="basketOverlay"></div><div class="basketPopup"><div class="basketClose"></div><div class="added hide"><div class="title">Added to follow up</div><div class="title2">Praxbind<sup>&reg;</sup> mode<br/> of action video</div><div class="cancel fragment1">CANCEL</div></div><div class="notadded hide"><div class="title">Not available</div></div></div><div class="basketItems"><div class="basketClose"></div><div class="title2">Shopping card</div><div class="noItems"><div class="title">No item added</div></div><div class="fragment f1"><div class="title">Praxbind<sup>&reg;</sup> mode<br/> of action video</div><div class="cancel frag1">CANCEL</div></div><div class="fragment f2"><div class="title">Pradaxa<sup>&reg;</sup> price <br/>reduction</div><div class="cancel frag2">CANCEL</div></div><div class="send">SEND</div></div></div></body></html>